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Purpose
15-30% of HAART-treated HIV-1-positive patients (pts)
lack CD4+ increase despite full HIV viremia suppres-
sion. The increased risk for INR to progress till AIDS
led us to investigate maraviroc (MVC) as a tool to
intensify HAART in terms of immunological recovery.
Methods
Randomised, multicentre, proof-of-concept study enrol-
ling 100 pts divided into 2 arms (1:1), A:HAART+MVC,
B:HAART. Inclusion criteria were: CD4 count ≥200
cells/µL and/or a recovery of CD4 cells <25% compared
to the HAART initiation and with a stable virologic sup-
pression after 1 year of HAART. Ultrasensitive HIV-
RNA was quantified via Amplicor HIV-1 Monitor Kit
v 1 . 5 .N a i v eC D 4 5 R A + ,m e m ory CD45RA-, activated
HLA-DR+CD38+, proliferating Ki67+, CD4+, CD8+ T-
cells were measured by flow cytometry. T-test was used
for intra and inter-group comparisons.
Results
100 pts have been randomized 64 pts reached week(w)
1 2 :3 7i nAa n d2 7i nBa r m s .A tb a s e l i n e( B L ) ,C D 4 /
CD8 and immune-phenotype were comparable in arm A
and B. At w12 no significant changes in mean CD4
recovery (+41.9 vs +24.5/µL; p=.241) and a statistically
significant change in mean CD8+ count (+164.2 vs
-27.3/µL; p=.004) were observed between pts in arm A
and B.
At BL and w12 an immunological study was carried
out in 24 pts (13:arm A, 11:arm B): at w12, while B pts
experienced a contraction of naïve CD4 (81 to 67%;
p=.02) and CD8 (81 to 77%; p=.04) with a parallel rise
in memory CD4 (16 to 30%; p=.02) and CD8 (13 to
17%; p=.06), no significant loss of naive CD4 (70 to
57%; p=.18) and CD8 (69 to 66%; p=.42) was displayed
by A pts with a tendency to higher gain in memory
CD4 (24 to 40%; p=.06) and CD8 (11 to 25%; p=.008).
By w12, a similar reduction in activated HLA-DR+CD38
+ CD8 and CD4 was shown in B (p=.05) and A pts
(p=.03 and p=.02 for CD8 and CD4). A trend to Ki67
+CD8 reduction was shown in A (p=.06) and not in B
pts (p=.45). HIV-RNA quantification evidenced a trend
to higher median values (BL vs w12) in B pts: 2 vs 5 cp/
mL (p=.37).
Conclusions
MVC does not seem to increase CD4 amount at signifi-
cant level compared to arm B. Treatment with MVC is
associated with a significant CD8+ gain, a preservation
of phenotypically naïve CD4+ and parallel rise of mem-
ory pool, suggesting a role of MVC in reducing periph-
eral antigen-driven T-cell death, possibly preserving new
T-cell production. MVC is able to further reduce T-cell
activation and proliferation, suggesting a possible influ-
ence in better controlling the pro-inflammatory status.
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